Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) announced that the National Medical Products Administration has approved the drug-registration application for Levosalbutamol Hydrochloride Nebuliser Solution, developed and manufactured by its subsidiary Fosun Pharma (Xuzhou) Co., Ltd.

The newly approved product is indicated for the treatment or prevention of bronchospasm in adults, adolescents and children aged six and above with reversible obstructive airway disease. It is classified as a Class 3 chemical drug and will be marketed under approval number Guo Yao Zhun Zi H202654902. The formulation is a 3 ml:0.63 mg nebuliser solution (calculated as C13H21NO3).

Fosun Pharma has invested approximately RMB5.66 million to bring the therapy to market as of June 2026. According to IQVIA CHPA data, China’s (excluding Hong Kong, Macau and Taiwan) market for Levosalbutamol Hydrochloride Nebuliser Solution reached around RMB73.00 million in sales during 2025, highlighting a measurable but modest revenue pool.

Management expects the approval to broaden the group’s respiratory portfolio; however, future sales will depend on market demand, competitive dynamics and distribution efficiencies, which may introduce variability in commercial outcomes.

The board affirms the accuracy and completeness of the disclosed information and reminds investors of potential market-performance uncertainties inherent in new pharmaceutical launches.